ACET

Adicet Bio, Inc. operates as a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for the treatment of cancer and other diseases. Headquartered in Menlo Park, California, the company leverages its proprietary gamma delta T cell platform to engineer off-the-shelf cell therapies that can be administered to multiple patients without the need for patient-specific manufacturing. Adicet's lead product candidate, ADI-001, is an allogeneic gamma delta T cell therapy targeting CD20-positive malignancies, including non-Hodgkin lymphoma. The company's pipeline also includes ADI-002, designed for solid tumors. Adicet employs its EXIT technology to selectively eliminate specific T cell populations, enhancing the therapeutic potential of its candidates. The company was founded in 2014 and completed its initial public offering in 2020. In recent developments, Adicet has advanced its clinical programs through Phase 1 trials while expanding its intellectual property portfolio in the gamma delta T cell space. The company collaborates with leading research institutions to explore additional applications of its platform technology. As a development-stage biopharmaceutical company, Adicet does not yet generate product revenue and funds its operations through equity financings and strategic partnerships. The company competes in the rapidly evolving field of allogeneic cell therapy alongside other biotechnology firms pursuing off-the-shelf immunotherapy approaches.